Biochemical and pathological studies on the effects of levamisole and chlorambucil on Ehrlich ascites carcinoma-bearing mice;Studi biochimici e patologici sugli effetti di levamisolo e clorambucile su topi portatori di carcinoma ascite di Ehrlich

Veterinaria Italiana

Volumn 47, Issue 1, 2011, Pages 89-95

  Salem, Fakhry S ^a   Badr, Mohamed O T ^a   Neamat Allah, Ahmed N F ^a  

^a Zagazig University   (Egypt)

Author keywords

Carcinoma; Chlorambucil; Control; Ehrlich ascites carcinoma; Levamisole; Mice

Indexed keywords

ALKYLATING AGENT; CHLORAMBUCIL; IMMUNOLOGICAL ADJUVANT; LEVAMISOLE;

ANIMAL; ARTICLE; BLOOD; EHRLICH ASCITES TUMOR; FEMALE; MOUSE; PATHOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOMA, EHRLICH TUMOR; CHLORAMBUCIL; FEMALE; LEVAMISOLE; MICE;

MUS;

EID: 79251542996     PISSN: 0505401X     EISSN: 18281427     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Badr M.S. 2007. Clinico-pathological studies on the effect of levamisole in rabbits. MVSc thesis (clinical pathology), Faculty of Veterinary Medicine, Zagazig University, Zagazig, 83 pp.
2. Baillif N.R. 1954. The solid phase of the Ehrlich ascites tumour in mice. Cancer Res, 4 (13), 554-561.
3. Begleiter A., Lee K., Israels L.G., Mowat M.R. & Johnston J.B. 1994. Chlorambucil induced apoptosis in chronic lymphocytic leukemia (CLL) and its relationship to clinical efficacy. Leukemia, 8, 103-106.
4. Coles E.H. 1986. Veterinary clinical pathology, 2nd Ed. W.B. Saunders Company, Philadelphia and London, 208-213.
5. Doumas B.T., Baysa D.D., Carter R.J., Peters T. & Schaffer R. 1981. Determination of serum total protein. Clin Chem, 27, 1642.
6. Drupt F. 1974. Colorimetric method for determination of serum albumin. Pharm Bio Sciences, 9, 777.
7. Findlay V.L. & Munday B.L. 2000. The immunomodulatory effects of levamisole on the nonspecific immune system of Atlantic salmon, Salmo salar L. J Fish Dis, 23, 369-378.
8. Friis T., Engel A.M., Klein B.M., Rygaard J. & Houen G. 2005. Levamisole inhibits angiogenesis in vitro and tumour growth in vivo. Angiogenesis, 8 (1), 25-34.
9. Garrison R.K., Galloway R.H. & Heuser L.S. 1987. Mechanism of malignant ascites production. J Surg Res, 42, 126-132.
10. Gartrell B.D., Alley M.R. & Mitchell A.H. 2005. Fatal levamisole toxicosis of captive kiwi (Apteryx mantelli). N Z Vet J, 53 (1), 84-86.
11. Griffin A.T., Dodd N.J., Zhao A., Pulfan R. & Moore V. 1995. Low level direct electrical current therapy for hepatic metastasis. Br J Cancer, 72 (1), 31-34.
12. Gumińska M., Kedryna T. & Marchut E. 1986. The effect of levamisole on energy metabolism in Ehrlich ascites tumour cells in vitro. Biochem Pharmacol, 35 (24), 4369-4374.
13. Husdan H. & Rapoport K. 1968. Chemical determination of creatinine with deproteinization. Clin Chem, 14, 222-238.
14. Krakowski L., Krzyzanowski J., Wrona Z. & Siwicki A.K. 1999. The effect of nonspecific immunostimulation of pregnant mares with 1,3/1,6 glucan and levamisole on the immunoglobulin levels in colostrum, selected indices of nonspecific cellular and humoral immunity in foals in neonatal and postnatal periods. Vet Immunol Immunopathol, 68, 1-11.
15. Naylor P.H. & Hadden J.W. 2003. T-cell targeted immune enhancement yields effective T-cell adjuvants. Int Immunopharmacol, 3 (8), 1205-1215.
16. Nygren P. 2001. What is cancer chemotherapy? Acta Oncologica, 40, 166-174.
17. Pal S., Bhattacharyya S., Choudhuri T., Datta G.K., Das T. & Sa G. 2005. Amelioration of immune cell number depletion and potentiation of depressed detoxification system of tumour-bearing mice by curcumin. Cancer Detect Prev, 29(5), 470-478.
18. Regato A.J, Harlan J. S. & Cox J.D. 1985. Cancer diagnosis and treatment and prognosis, 6th Ed. C.V. Mosby Company, St Louis, 243 pp.
19. Reitman S. & Frankel S. 1957. A colorimetric method for determination of serum glutamicoxaloacetic transaminase and serum glutamic pyruvic transaminase. Am J Clin Pathol, 25, 56.
20. Sienkiewicz P., Bielawski K., Bielawska A. & Pałka J. 2005. Inhibition of collagen and DNA biosynthesis by a novel amidine analogue of chlorambucil is accompanied by deregulation of β1-integrin and IGF-I receptor signaling in MDA-MB 231 cells. Environ Toxicol Pharmacol, 20, 118-124.
21. Tamhane A.C. & Dunlop D.D. 2000. Statistic and data analysis from elementary to intermediate. Prentice Hall, Upper Saddle River, 85 pp.
22. Tofani S., Cintorino M., Barone D., Berardelli M., De Santi M.M., Ferrera A., Orlassino R., Ossola P., Rolfo K., Ronchetto F., Tripodi S.A. & Tosi P. 2002. Increased mouse survival, tumor growth inhibition and decreased immunoreactive p53 after exposure to magnetic fields. Bioelectromagnetics, 23 (3), 230-238 (www.care-nexus.com/images/Increased_mouse_survival_tumor.pdf accessed on 31 December 2010).
23. Wolverton S.E. & Remlinger K. 2007. Suggested guidelines for patient monitoring: hepatic and hematologictoxicity attributable to systemic dermatologic drugs. Dermatol Clin, 25 (2), 195-205.